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Abstract: UBE2O as an atypical ubiquitin-conjugating enzyme possesses an E2-E3 hybrid enzyme activity. It can regulate substrate
levels or transcriptional activities by cooperating with other E3 ubiquitin ligases or forming homomeric complexes displaying intrinsic
E2 and E3 activities. UBE2O controls the quality of cell proteome including protein degradation, modification, transport and location.
Recent studies reveal that UBE2O plays a vital role in intracellular protein ubiquitination processes by regulating BMP/SMAD, TRAF/
NF-κB, mTOR/HIF1a and IL-1β/IRAK4 signaling pathways, c-Maf stability and BAP1 subcellular location, which is proposed as a
quality control supervisor of multiprotein complexes for degradation. Its abnormality leads to a variety of physical activity disorders and
even occurrence of cancer. UBE2O is entirely distinct in molecular structure and functions from other E2 ubiquitin ligase. Exploring
and elucidating regulatory mechanism of UBE2O may identify novel crucial molecular targets so as to pave therapeutic approaches for
ubiquitination-associated metabolic disorders and diseases. Here, we particularly feature regulatory pathways of UBE2O in orphans of
multiprotein complexes for degradation and its potential application.
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1. Introduction
Ubiquitination is a process of ubiquitin covalent
attachment to target proteins, including three main steps:
activation, conjugation and ligation, which regulates
protein activity, degradation, cellular location and proteinprotein interaction (Cai et al., 2017; Tsuchida et al., 2017).
There are several types of substrate ubiquitination, such
as monoubiquitination, multimonoubiquitination and
polyubiquitination. The anomalous ubiquitin pathway has
been involved in the pathogenesis of many diseases and
genetic disorders. Ubiquitination requires the cooperation
of E1s (ubiquitin activating enzymes), E2s (ubiquitin
conjugating enzymes) and E3s (ubiquitin ligases).
Nowadays, over 35 E2 enzymes have been identified in the
human, but their functions still need to be clarified (Van
and Timmers, 2010).
Ubiquitin-conjugating enzyme E2O (UBE2O) is also
named as E2-230K which was first purified from rabbit
reticulocytes in 1989 (Klemperer et al., 1989). Yokota
T and colleagues identified UBE2O located in 17q25.1
via YAC and PAC genomic clones (Yokota et al., 2001).
UBE2O is an atypical E2 ubiquitin enzyme containing an
UBC domain with 56 conserved amino acid residues and
it also possesses E3 activity (Figure 1). Studies have shown
that UBE2O N-terminal portion can selfinteract with

C-terminal portion and directly incurs ubiquitination of
several substrate in the presence of only the E1 enzyme
such as BAP1, SMAD6, AMPKa2, c-Maf, MLL and
BMAL1 (Zhang et al., 2013; Mashtalir et al., 2014; Liang et
al., 2017; Vila et al., 2017; Xu et al., 2017). It also displays
functionally regulating activity that is independent of its
E2 activity (Zhang et al., 2013). Unlike most members
of E2s, molecular weight of UBE2O (140 kDa) is much
larger than other E2 ubiquitin-conjugation enzymes (1435KDa). It is expressed in a great number of organs and
tissues, but predominantly in skeletal muscle, brain and
heart tissues (Yokota et al., 2001; Zhang et al., 2013).
UBE2O also show high-expression during the reticulocyte
period of erythroid differentiation, which is believed to
play a critical role in the terminal erythroid differentiation.
Markson et al. found through yeast two-hybrid screens
that more than 100 E3 ubiquitin ligases have the ability to
interact with UBE2O.
It was further found that UBE2O can modulate
expressions of ribosomal proteins RPL29, RPL35 and
RPL23A, and nonribosomal proteins DDX5, NOL12,
NOP16 and PTRF (Nguyen et al., 2017). It affects cell
proliferation via regulating BAP1, FOXK1, FOXK2 and
KDM1B levels (Mashtalir et al., 2014), and cell cycle via
regulating ALDOA, EGR1, GNA15, LGALS1, PE2RY11
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and SREBF1 expressions (Liang et al., 2017). Zhang
et al. reported that UBE2O also impacts activities of
transcriptional factors TRAF6, NF-κB, etc. (Zhang et al.,
2013; Ullah et al., 2019). In addition, UBE2O can function
in BMP7-induced adipogenesis via monoubiquitination
of SMAD6 and also in chromatin remodeling by
ubiquitinating the tumor-suppressive DUB BAP1
(Hormaechea-Agulla et al., 2018). However, the functions
of UBE2O remain mostly unknown (Markson et al., 2009).
Recently, several in vitro and in vivo studies demonstrated

that UBE2O is implicated in several cellular pathways
(Table). In this paper, we feature current literatures about
possible roles of UBE2O in cellular signal transductions to
provide a novel insight into pathogenesis of some clinical
disorders and pathological processes.
2. UBE2O
augments BMP signaling by
monoubiquitination of SMAD6
Bone morphogenetic proteins (BMPs) have been
implicated in cell proliferation, differentiation and

Figure 1. Structure and its position of UBE2O on the chromosome. The genomic location of UBE2O is on human 17q25.1 and its
whole length is 63.7 kb. The human UBE2O cDNA length is 4878 nucleotides encoding 1138 amino acids which contain a 56 amino
acid conservative residue UBC domain. UBE2O is E2/E3 hybrid ubiquitin-protein ligase that possesses both E2 and E3 ligase activities
and mediates monoubiquitination of target proteins.
Table. Signal pathways and functions of UBE2O.
Substrate Pathway

Function

Reference

WASH

WASH/F-actin

Promoting retrograde transport

[33]

SMAD6

BMP7/SMAD6

Inducing adipocyte differentiation

[7]
[11]

TRAF6

TRAF6/NF-κB

Preventing the activation of NF-κB by IL-1β and LPS

BAP1

Indetermination

Regulating BAP1 subcellular localization and disturbing cell proliferation [9]
Disturbing stability of MLL and augmenting MLL leukemia

MLL

Indetermination

AMPKa2

AMPKa2/mTOR/HIF1a Facilitating breast and prostate cancers

[10]

c-Maf

Indetermination

[8]

Promoting c-Maf degradation and depressing multiple myeloma

[6]

BMAL1

Indetermination

Modulating circadian rhythm

[35]

RPs

Indetermination

Remodeling erythroid proteome

[37]

Non-RPs

Indetermination

Indetermination

[37]

187

LV and XING / Turk J Biol
apoptosis, which were identified on the basis of their ability
to promote the formation of bone and cartilage (Miyazono
et al., 2010; Plouhinec et al., 2011). BMPs induce a type II
receptor binding to a type I receptor to form a heteromeric
complex, activating a type I receptor (also named activin
receptor-like kinases, ALKs). Activated ALKs deliver the
intracellular signal to activate receptor-regulated SMADs
(R-SMADs), such as SMAD1/5/8. Then, phosphorylated
R-SMADs interact with common-mediator SMAD (coSMAD, i.e. SMAD4) to form heteromeric complexes
and translocate into the nucleus to regulate target genes.
SMAD6 is one of the BMP signaling target genes, which
plays a role in feedback regulation (Itoh and Ten, 2007;
Sieber et al., 2009). Whole proteomic tandem affinity
purification assay preformed in HEK293T cells showed
that UBE2O interacts with SMAD6, which has been
proved by cotransfection of labeled proteins. SMAD6
monoubiquitination by UBE2O attenuated binding affinity
between SAMD6 and ALK2. In fact, the regions of SMAD6
C-terminal and UBE2O N-terminal are indispensable for
their interaction. UBE2O contains a UBC domain, which
has the E2 activity that can induce the monoubiquitination
of SMAD6. RNAi or mutation of cysteine 885, which
is in UBC domain of UBE2O, attenuates the level of
monubiquitinated SMAD6. To be noted, mutated lysine
174 in the region of SMAD6 N-terminal significantly
reduced the monoubiquitination levels caused by UBE2O,
which implies that UBE2O is mainly responsible for
the monoubiquitination of SMAD6 through lysine 174.
Moreover, mutation of SMAD6 lysine 174 more obviously
inhibited BMP7-induced SMAD1 phosphorylation (Zhang
et al., 2013). On the other hand, the expressional level of
UBE2O appears to be a positive correlation with BMP7
to promote adipocyte differentiation. HepG2 cells treated
with UBE2O-specific shRNAs significantly impaired
BMP7-induced signal activation and the phosphorylation
level of SMAD (Figure 2). Further studies showed that the
nonmodified SMAD6 protein displayed in all subcellular
fractions, whereas monoubiquitinated SMAD6 was mainly
located in the cytoplasm. These results show that the
monoubiquitination of SMAD6 via UBE2O predominantly
occurs in the cytoplasm and influences the upstream
of SMAD1 phosphorylation. Besides, the catalytically
inactive mutant (C885S) of UBE2O is disable to facilitate
BMP7-induced SMAD transcriptional responses (Zhang
et al., 2013), suggesting that the monoubiquitination of
SMAD6 by UBE2O enhances BMP7/SMAD signaling to
induce adipocyte differentiation.
3. UBE2O inhibits TRAF6-mediated NF-κB activation
Tumor necrosis factor (TNF) receptor-associated factor
6 (TRAF6) has been proved to play a pivotal role in the
interleukin-1 receptor (IL-1R) or Toll-like receptor (TLR)mediated innate immunity (Barton and Medzhitov, 2003;
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Xing et al., 2017). IL-1R/TLR recognizes ligands such as
cytokines IL-1β or pathogen-associated molecular pattern
lipopolysaccharides (LPS) to recruit the adaptor proteins
IL-1R-associated kinase 1/4 (IRAK1/4) and myeloid
differentiation primary response gene 88 (MyD88). Then
IRAK1/4 and MyD88 form a complex with TRAF6 and
trigger TRAF6 lysine 63 auto-ployubiquitination via
ubiquitin-conjugating enzyme 13 (UBC13)/Uev1a (Deng
et al., 2000). The auto-polyubiquitination of TRAF6
activated TGF-β activated kinase 1 (TAK1) to trigger the
degradation of the downstream κ-light-chain enhancer of
activated IκBα, which will lead to the phosphorylation of
NF-κB, be located to the nucleus and initiate target gene
transcriptional responses (Wang et al., 2001). Thus, the
polyubiquitination of TRAF6 plays a critical role in NF-κB
signal transduction.
Yeast two-hybrid and coimmunoprecipitation assays
demonstrated that the putative E2 enzyme UBE2O
interacted with several TRAF family members including
TRAF1, TRAF3, TRAF4, TRAF5 and TRAF6. However,
UBE2O has the most powerful effects on NF-κB activation
that is mediated by TRAF6 (Markson et al., 2009; Zhang
et al., 2013). Importantly, UBE2O particularly prevents
IL-1β or TLR4-triggered NF-κB activation rather than
poly (I: C) or TRIF in a dose-dependent manner. Besides,
UBE2O also inhibits the activation of NF-κB reporter
induced by MyD88, rather than IKKs or p65. Hence, these
results imply that UBE2O functions in the upstream in
the TRAF6-mediated NF-κB signaling pathway (Zhang
et al., 2013). Overexpression of UBE2O suppresses the
IL-1β-induced phosphorylation and degradation of IκBα, and the expression of NF-κB-targeted genes including
IL-6, TNF-α, CCL2 and NOS2 (Figure 3). Consistent with
the above, knockdown of UBE2O augments the IL-1β or
LPS-induced NF-κB activity and the expression of NF-κB
target genes. It should be noted that UBE2O also reduces
the phosphorylation of JNK or p38 induced by IL-1β
(Zhou et al., 2012). Further investigations demonstrated
that UBE2O strongly reduced the polyubiquitination
level of TRAF6 whether IL-1β stimulation exists or not.
Besides mainly inhibiting the polyubiquitination of K63,
UBE2O also blocked the polyubiquitination of TRAF6
K48. Strikingly, the N-terminal UBC domain of UBE2O
is dispensable for inhibition of the TRAF6-induced NFκB activity. The C-terminal deletion mutant (D1) can
efficiently interact with TRAF6, which contains a coiledcoil interaction domain but lacks the UBC domain. On the
contrary, the N-terminal deletion construct (D2), which
contains the UBC domain but lacks the coiled-coil domain,
cannot combine with TRAF6. Coimmunoprecipitation
analysis by three TRAF6 deletion constructs showed
that the C-terminal TRAF domain is indispensable for
interaction with UBE2O. What is noteworthy is that the
domain is also necessary for the TRAF6 interaction with
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Figure 2. UBE2O augments BMP signaling by monoubiquitination of SMAD6. a. SMAD6 negative feedback regulates BMP-induced
adipocyte differentiation. b. UBE2O induces the monoubiquitination of SMAD6 to strengthen the adipocyte differentiation which is
activated by BMP signaling cascade.
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Figure 3. UBE2O inhibits TRAF6-mediated NF-κB activation. a. IL-1β/LPS activates NF-κB signal by inducing TRAF6 autoployubiquitination. b. UBE2O replaces the place of MyD88 to prevent the activation of NF-κB that is induced by the polyubiquitinated
TRAF-6.

upstream protein MyD88. Importantly, forced expression
of UBE2O impaired the interaction between TRAF6 and
MyD88 rather than other upstream proteins, such as the
combination between TRAF6 and IRAK1 or MyD88 and
IRAK4 (Zhang et al., 2013). These results suggest that
UBE2O perhaps plays a role to disturb the interaction
between TRAF6 and its regulator MyD88, attenuating
TRAF6-polyubiquitination and subsequent NF-κB
activity.
4. UBE2O mediates BAP1 subcellular location
BRCA1 associated protein-1 (BAP1) is a deubiquitination
enzyme that implicates in cell proliferation and
tumorigenesis via interaction with chromatin associated
proteins (CAPs) (Misaghi et al., 2009; Dey et al., 2012).
Recently, it was revealed that UBE2O could be copurified
with BAP1, implying that it is likely to be implicated in the
regulation of BAP1 function (Sowa et al., 2009; Mashtalir
et al., 2014). Mashtalir et al. found that UBE2O not only
interacts with wild-type, but also catalytic dead BAP1
(C91S) (Yu et al., 2010). In fact, BAP1 is functionally
regulated by several ubiquitination events in the both
deubiquitinase (DUB)-activated or nonactivated ways.
Investigated several E2s and DUBs demonstrated that
UBE2O is specifically directed against ubiquitination of
BAP1. The conserved region 1(CR1), conserved region
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2 (CR2), and UBC domains of UBE2O are necessary
for the ubiquitination of BAP1 because deletion of
anyone of them abolishes the ability of UBE2O to bring
ubiquitination of BAP1. In vitro and vivo experiments
using methylated ubiquitin or K0 ubiquitin mutant, which
is unable to form polyubiquitin chains, showed a similar
ubiquitination pattern of unmodified ubiquitin. Besides,
the proteasome inhibitor MG132 cannot influence the
UBE2O-mediated multimonoubiquitination pattern
of BAP1 in 293T cells co-transfected with UBE2O
and BAP1 or C91S mutant. These results implied that
UBE2O catalyzes multimonoubiquitination of BAP1,
but is incapable of polyubiquitin chain elongation and
subsequent degradation of BAP1 (Mashtalir et al., 2014).
Further studies indicate that the NLS regions of BAP1
including the RRR site on aa 699–701, the hydrophobic
GVSIGRL patch on aa 703–709 and the basic amino
acid stretch RRKRSRPYKAKRQ on aa 717–729 are
indispensable for combination and ubiquitination by
UBE2O. MS peptide analysis showed that BAP1 possesses
14 unique ubiquitination sites. Of note, 50% ubiquitination
sites are located in the NLS area that occupies only 4%
of the whole proteins. Mutation of lysine sites (K/R) in
NLS significantly attenuated C91S ubiquitination. Under
natural physiological conditions, BAP1 is mainly located
in nuclear and UBE2O is predominantly in cytoplasm.
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When coexpressed with UBE2O, BAP1 showed the strong
ubiquitin-mediated nuclear export (Figure 4). These results
suggest that UBE2O regulates BAP1 nucleocytoplasmic
transport and subcellular localization, and mediates the
occurrence of diseases by ubiquitination of the NLS of
BAP1 (Mashtalir et al., 2014). As a matter of fact, BAP1
contributes to NLS autodeubiquitination against UBE2O
ubiquitination by its intramolecular interaction. Mutation
of BAP1 disrupts its autodequitination, lending to
inappropriate BAP1 localization, which may be another
important causes in the occurrence of diseases.
5. UBE2O enhances interleukin-1 pathway-induced
MLL degradation
Mixed-lineage leukemia (MLL) has been reported to
translocate with over 70 partner genes to form diverse
oncogenic MLL chimeras, which result in deregulation
of target genes and aggressive leukemia (Meyer et al.,
2013; Pigneux et al., 2015). These MLL rearrangements
mainly occur in pediatric patients and are associated with
the poorest prognosis of acute leukemia (Mohan et al.,
2010). The MLL chimeras consist of a MLL N-terminal
fragment and a C-terminal portion of its partner. Liang
et al. found that although wild-type MLL and chimeric
MLL have similar mRNA expression, wild-type MLL is
much less than the MLL chimeras in the protein level in

MLL leukemia cell lines. Therefore, they hypothesized
that stability of the wild type MLL protein may replace
the MLL chimeras from chromatin and relieve leukemia.
Due to that MLL chimeras possess the same N terminal
with wild-type MLL, but absent the internal regions
in the C-terminal that are responsible for protein
breakpoint. These missing regions may be tightly related
to the stabilization of MLL. Multidimensional protein
identification technology (MudPIT) assay showed UBE2O
to be the most abundant protein specifically interacting
with MLL internal region (MLL-Inter), which was also
confirmed by coimmunoprecipitation. The UBE2O could
not bind the most common MLL chimeras including MLLENL, MLL-AF9, MLL-AFF1 and MLL-ELL (Liang et al.,
2017). In fact, the first PHD finger domain and the region
spanning the MLL breakpoint region are necessary and
adequate for the interaction between MLL and UBE2O.
Overexpression of UBE2O significantly induced
proteasome-mediated MLL degradation in HEK293 cells.
In agreement, knockdown of UBE2O by two independent
shRNAs increased wild-type MLL protein levels. Further
studies demonstrated that IL-1β markedly induces the
MLL degradation and promotes the interaction of UBE2O
and MLL-Inter. Ectopic expression of UBE2O increases
the ubiquitination of MLL-Inter, which could be further
enhanced by the stimulation of IL-1β. Moreover, IRAK4

Figure 4. UBE2O mediates BAP1 subcellular location. a. BAP1 maintains the ability of nucleocytoplasmic transport by autodequitination.
b. UBE2O regulates BAP1 nucleocytoplasmic transport and subcellular localization and mediates the occurrence of diseases by
ubiquitination of the NLS of BAP1.
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could directly phosphorylate UBE2O and deletion of
IRAK4 or treatment with IRAK4 inhibitor represses the
MLL-UBE2O interaction, indicating that IL-1β/IRAK4/
UBE2O signaling mediates the degradation of MLL.
Deletion of UBE2O or cells treated with IRAK4 inhibitor
result in a greater inhibition in MLL-dependent (SEM)
cell proliferation, compared to non-MLL (REH) cells.
In fact, overexpression of the MLL N-terminus of MLL,
which cannot bind UBE2O but contains chromatinbinding domains, reduced the proliferation of SEM cells,
indicating that destabilizing wild-type MLL is prerequisite
for the proliferation of MLL leukemia cells (Liang et al.,
2017). Inhibition of IRAK4 to regulate UBE2O markedly
increases the chromatin occupation of wild-type and
inhibits the proliferation of MLL leukemia, which
provides us a paradigm to develop a novel therapy method
for aggressive MLL leukemia and other cancers caused by
improper translocation.
6. UBE2O promotes activation of the mTOR-HIF1a
pathway by the ubiquitination degradation of AMPKa2
Recent studies showed that UBE2O is amplified in
several human cancers including liver, beast, bladder and
lung carcinoma, indicating UBE2O may exert a positive
effect on cancer cell survival (Briffa et al., 2015; Vila et
al., 2017). Moreover, classical focus formation assays by
adenovirus H-RasV12 and E1A revealed Ube2o-/- mouse
embryonic fibroblasts (MEFs) have lesser number of
foci of morphologically transformed cells than wild-type
cells, indicating that UBE2O promotes cellular oncogenic
transformation. To examine the function of UBE2O
in vivo, Vila and his colleagues crossbred the Ube2o
knockout mouse with two transgenic mouse models of
spontaneous cancer (MMTV-PyVT mice for breast cancer
and TRAMP mice for prostate cancer). UBE2O ablation
in MMTV-PyVT mice markedly inhibits breast cancer
initiation, progression, angiogenesis and lung metastasis.
Similarly, knockout of UBE2O in TRAMP mice improves
prostate cancer survival, invasion and metastasis. These
results suggest that UBE2O might be a new therapeutic
target for cancer.
Mechanistic researches showed that UBE2O has the
ability to bind AMPKa2 protein leading to ubiquitination
on its lysine-470 (K470) residue, which is a conserved
residue in AMPKa2 of vertebrate species but substituted by
an arginine (R475) in AMPKa1. UBE2O promoted K48linked ubiquitination degradation of AMPKa2 in vitro and
in vivo, but not AMPKa1 (Vila et al., 2017). Furthermore,
knockdown of UBE2O increased AMPKa2 protein levels,
leading to a strong activation of its downstream target
genes. Ube2o ablation in two mouse models of lymphoma
(an Em-Myc mouse model of B cell lymphoma and a Ptendeficient mouse developing T cell lymphoma) in which
AMPKa2 is undetectable, did not produce a markedly
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antitumor effect, suggesting that AMPKa1 might not
play a role in UBE2O-dependent tumorigenesis (Vila et
al., 2017). Further studies showed that UBE2O promoted
the activation of the rapamycin complex 1 (mTORC1)
signaling and downstream hypoxia-inducible factor 1-a
(HIF1a) through S6 phosphorylation in an AMPKa2dependent manner. The test of UBE2O inhibitor ATO in
mouse models of breast and prostate cancers demonstrated
that it can reduce tumor incidence and progression, and
extend mouse survival (Vila et al., 2017). Hence, these
results indicate that UBE2O is a new cancer therapeutic
target, which modulates the AMPKα2-mTOR-HIF1α axis.
7. UBE2O induces myeloma cell apoptosis via
modulating c-Maf stability
Transcription factor c-Maf is a member of Maf family,
which highly expresses in over 50% of primary multiple
myeloma (MM) patient samples and MM cell lines. c-Maf
significantly enhances myeloma cell proliferation in vitro
and tumor formation in vivo. c-Maf transgenic mice
display the MM-like symptoms. From these results c-Maf
has been considered as an important regulator to the MM,
which could be a target for MM therapy (Hurt et al., 2004).
Zhang et al. discovered that c-Maf goes through
degradation by the ubiquitin proteasome pathways and
destabilizing c-Maf inhibits the growth of MM xenografts
in mice, but its ubiquitin conjugating enzyme is not clear
(Zhang et al., 2016). LC/MS/MS assay to analyze the c-Maf
specific antibody affinity products demonstrated that
UBE2O is a unique ubiquitin conjugating enzyme, which
is also proved by immunoprecipitation. The ubiquitination
assay in tube revealed that UBE2O markedly increases the
level of c-Maf ubiquitination without an extra E3 ligase.
Moreover, cotransfected c-Maf and UBE2O with the
mutated ubiquitin plasmid K48R or K63R in HEK293T cells
revealed that the K63R-Ub mediated the ubiquitination
of c-Maf, but not K48R, indicating that UBE2O mediates
the polyubiquitination c-Maf at K48. On the other hand,
MG132 treatment abolishes the degradation of c-Maf
protein that is mediated by UBE2O. These results suggested
that UBE2O mediates the polyubiquitination of c-Maf at
K48 and degradation in the proteasome pathway. It was
found by a series of mutants of lysine (K) to arginine (R)
that the K331 and K345 residues of c-Maf were necessary
for interacting with UBE2O. Further researches illustrated
that UBE2O induced MM cell apoptosis and suppressed
cell proliferation both in vitro and in vivo, which is
associated with the c-Maf expression protein level. Based
on the above results, UBE2O mediating c-Maf stability
may be a novel insight to myeloma therapy.
8. Conclusion
UBE2O participates in regulating the degradation of
orphans of multiprotein complexes, hereby influencing
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occurrence of diseases. It binds SMAD6/SMAD7 to
partially contribute to BMP/SMAD signal regulation to
induce adipocyte differentiation. UBE2O can disturb
the interaction between TRAF6 and its regulator
MyD88, attenuating TRAF6-polyubiquitination and
subsequent NF-κB activity. UBE2O also regulates BAP1
nucleocytoplasmic transport and subcellular localization
to mediate the occurrence of diseases by ubiquitination of
the NLS of BAP1. It induces myeloma cell apoptosis via
modulating c-Maf stability and is intimately associated
with occurrence of esophageal and breast cancer due to
the deficiency of 17q25.1, possibly becoming a new cancer
therapeutic target through modulating the AMPKa2mTOR-HIF1a axis. UBE2O may affect endosomal protein
trafficking and cell proteome through retromer-mediated
transportation and endosomal F-actin (Hao et al., 2013).
It also recognizes ribosomal proteins and other substrates
to induce erythroid proteome to undergo a rapid and
drastic change at the reticulocyte stage (Nguyen et al.,
2017). Importantly, UBE2O has been suggested as a
quality control supervisor of multiprotein complexes
for degradation (Yanagitani et all., 2017). Hence, the

progression on UBE2O provides a new perspective to
develop drugs by regulating UBE2O activity. However,
the current understanding of UBE2O is quite limited and
the detailed regulatory mechanisms remain to be unclear.
Although it is revealed that UBE2O exerts the E3 activity
in N-terminal portion, further researches need to identify
the cysteine residue which functions as an E3 active site.
Besides its E2-E3 activity, other actions of UBE2O merit to
be explored as well. Together, UBE2O plays a vital role in
intracellular protein ubiquitination regulation. Elucidating
the functions of UBE2O may lead to identification of
neoteric crucial molecular targets so as to pave therapeutic
approaches for ubiquitination-associated metabolic
disorders and diseases.
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